DIRS.INFO The most relevant business & tech news

☆ 2024’s safest sunscreens for summer and year-round
▼ + stars: | 2024-05-01 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +10 min

The annual report provides a database of products by brand and type, while also breaking them down into the top recreational sunscreens, the best daily SPF (sun protection factor) and the safest sunscreens for babies and children. Many of the safest choices will be mineral-based instead of chemical-based sunscreens, said Emily Spilman, EWG’s healthy living science program manager. Mineral sunscreens work by physically deflecting and blocking the sun’s rays, as opposed to sunscreens with chemicals that absorb UV rays and release heat as they break down. In 2019, oxybenzone was an ingredient in 60% of all sunscreen products tested by EWG, dropping to 30% in 2022. By 2023 and again in 2024, the chemical was used in only 6% of tested products, which included sunscreens and daily moisturizers and lip balms with sunscreen protection.

Persons: Brianna Starr, Alicia, ” Brianna, we’d, “, ”, Brianna, Rajesh Nair, ” Nair, Emily Spilman, ” Spilman, It’s, “ It’s, Bill Clinton, padimate, Homer Swei, EWG’s, ” Swei, oxybenzone, Len Lichtenfeld, Lichtenfeld, ” Lichtenfeld Organizations: CNN, Orlando Health Cancer, Orlando Health Cancer Institute, Twitter, FDA, US Food and Drug Administration, Care Products Council, U.S . Food, Drug Administration, oxybenzone, American Cancer Society Locations: Kansas, TikTok, Orlando , Florida, Japan, Europe, U.S, Australia

☆ Daiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'
▼ + stars: | 2024-04-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDaiichi Sankyo shares growth projections, says its oncology business is a 'growth driver'Hiroyuki Okuzawa, president and COO of the Japanese pharma company, discusses the company's results and growth projections.

Persons: Hiroyuki Okuzawa Organizations: Japanese pharma

One strategist, however is looking keenly at European equities, and notes that "Europe isn't a boring market." "You would hope that will translate through to the stock market in terms of company earnings growth in Europe. "While you might see some kind of short-term downturn, in the longer-term the picture is very positive for the sector," Field added. He sees value in payments, which he described as "one of the most undervalued parts of European financial services." The sector has trailed market performance, with valuations looking "interesting" over the last 12 months, Morningstar noted in its recent report.

Persons: Michael Field, Field, Morningstar Organizations: CNBC Pro, European Central Bank, Consumer, Swatch Group, Financial, Morningstar, ING Bank, Group, Health, Novo Nordisk Locations: U.S, Europe, Netherlands, British, Swiss

☆ AstraZeneca tops first-quarter revenue and profit expectations
▼ + stars: | 2024-04-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca tops first-quarter revenue and profit expectationsAstraZeneca CEO Pascal Soriot outlines how the pharma giant's first-quarter results were boosted by demand for its rare blood disorder and oncology drugs.

Persons: Pascal Soriot Organizations: AstraZeneca, pharma

☆ Here are Monday's biggest analyst calls: Apple, Nvidia, Tesla, Meta, Amazon, Microsoft, Spotify, Ferrari & more
▼ + stars: | 2024-04-22 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley lowered its price target on the stock to $210 per share from $220 but says it's sticking with Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon earnings next week. Bank of America reiterates Tesla as neutral Bank of America said it's sticking with its neutral rating on Tesla shares. Morgan Stanley upgrades Alcoa to equal weight from underweight Morgan Stanley said it sees a more balanced risk/reward for shares of Alcoa. Bank of America reiterates Apple as buy Bank of America says Apple is a top pick at the firm.

Persons: Goldman Sachs, Goldman, Morgan Stanley, it's, Piper Sandler, Piper, Apple, Q, Q revs, Papa, Stifel, Papa John's, Jefferies, Mizuho, JPMorgan, Raymond James downgrades, Raymond James, TD Cowen, BRBR, BMO downgrades, Tesla, Oppenheimer Organizations: Nvidia, NVIDIA, RBC, Apple, Microsoft, Meta, Bank of America, JPMorgan, Cisco, Deutsche Bank, Realty Trust, Deutsche, Brands, BMO, of America, Alcoa, Kymera Therapeutics, " Bank of America Locations: Singapore, Asia, Brazil

☆ Cancer cases in younger people are rising sharply. Here are some preventive measures to take
▼ + stars: | 2024-04-18 | by ( Katia Hetter | ) edition.cnn.com time to read: +8 min

Does this mean people should start screening for cancer at younger ages? In the United States, lung cancer, colorectal cancer, pancreatic cancer and breast cancer are the four top causes of cancer deaths. For instance, in the United States, the US Preventive Services Task Force recommends that people begin colon cancer screenings at age 45. One in 3 people who are eligible for colon cancer screenings have never received any screening exams, according to the American Cancer Society. As little as one or two minutes of vigorous exercise a day can lower cancer risk, as can reducing ultraprocessed food.

Persons: Leana Wen, Wen, hasn’t, It’s Organizations: CNN, American Cancer Society, George Washington University, Oncology, US Preventive Services Task Force, Brigade Locations: United States

☆ Trump’s Trial Enters Third Day With 7 Jurors Chosen
▼ + stars: | 2024-04-18 | by ( Ben Protess | Jonah E. Bromwich | ) www.nytimes.com time to read: +1 min

Seven jurors down, five more to go. The case against Mr. Trump stems from a hush-money payment to a porn star, Stormy Daniels, who during the 2016 presidential campaign threatened to go public with her story of a sexual encounter with Mr. Trump. Prosecutors say Mr. Trump concealed her story, and others, to influence the election. But prosecutors say he falsified business records to cover up the sex scandal, and charged him last year with 34 felony counts. Many expected jury selection to be a weekslong slog, but seven jurors were seated on Tuesday afternoon.

Persons: Donald J, Trump, Stormy Daniels, Daniels, Juan M Organizations: Prosecutors, Disney Locations: Ireland, Puerto Rico, Harlem

New York CNN —Jury selection in Donald Trump’s hush money business fraud case began Thursday looking like the task of finding 12 jurors had run aground. Juror 11 was seated on the jury after Merchan denied Trump’s challenge to the juror for cause. Trump’s lawyers argued she should be dismissed because she said she does not like Trump’s “persona.”“I don’t like his persona,” she said. The district attorney’s office refused. Trump’s attorneys and the district attorney’s office also will get additional peremptory challenges for the alternate jurors.

Persons: Donald Trump’s, Juan Merchan’s, It’s, won’t, topsy turvy, Trump, Merchan, ”, “, “ It’s, Trump’s, it’s, Susan Necheles, she’d, Michael Cohen, he’s, Todd Blanche, Josh Steinglass, “ We’re, ” Merchan, Blanche, “ They’re, what’s, Sandoval, they’ll, Jean Carroll, that’s Organizations: New, New York CNN, Trump, CNN, Twitter Locations: New York, Manhattan, New Yorker

☆ Biotech stocks are ready to break out. They just need one more thing
▼ + stars: | 2024-04-10 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.

Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey

☆ Study links accelerated aging to cancer risk in younger adults
▼ + stars: | 2024-04-07 | by ( Brenda Goodman | ) edition.cnn.com time to read: +6 min

CNN —Researchers looking for clues about why some types of cancer are on the rise in younger adults say they’ve found an interesting lead: a connection to accelerated biological aging. What faster aging could tell us about cancer riskAfter adjusting the data for factors they thought might bias their results, the researchers found that accelerated aging was associated with increased risk for cancer. “There are medications that also look like they can slow down accelerated aging,” said Blaes, who is testing two of them in cancer survivors. Cancer survivors often show greater biological aging, perhaps because of the after effects of therapies like chemotherapy and radiation. It’s not quite prime time, where we would go out and prescribe those medications for people, but this is really, really important work,” Blaes said.

Persons: they’ve, It’s, ”, Yin Cao, Louis, Cao, Tian, ” Cao, Anne Blaes, “, Blaes, Dr, Sanjay Gupta, ” Blaes Organizations: CNN, Washington University School of Medicine, American Association of Cancer, University of Minnesota, Hematology, Oncology, UM, CNN Health, Cancer Locations: St, San Diego

☆ Here are Thursday's biggest analyst calls: Nvidia, Tesla, Super Micro, Meta, Wynn, Reddit, Coinbase, GM & more
▼ + stars: | 2024-04-04 | by ( Michael Bloom | ) www.cnbc.com time to read: +10 min

Mizuho reiterates Nvidia as a top pick Mizuho says Nvidia is still a top idea at the firm. Morgan Stanley initiates Mural Oncology at overweight Morgan said in its initiation of the biotech company that it sees a long "cash runway" lasting through 2025. Morgan Stanley downgrades Block to underweight from equal weight Morgan Stanley sees growth headwinds for the payment tech company. Morgan Stanley upgrades Zeta to overweight from equal weight Morgan Stanley said the marketing technology company has an underappreciated valuation. " Morgan Stanley reiterates Tesla at overweight Morgan Stanley lowered its price target to $310 per share from $320. "

Persons: Bernstein, Reddit, underperform Bernstein, Raymond James, Raymond James downgrades Bumble, Barclays downgrades Ferrari, it's, Mizuho, Goldman Sachs, Goldman, Morgan Stanley, Morgan, Wolfe, underperform Wolfe, Piper Sandler, Piper, Synopsys, Morgan Stanley downgrades Block, Dave, Buster's, Jefferies, Zeta, Oppenheimer, Ball, Wayfair, Wynn, bullish, Tesla, Goldman Sachs downgrades Hertz Organizations: Citi, Barclays, Ferrari, Nvidia, JPMorgan, Avis, UBS downgrades Bank of America, UBS, Apple, AstraZeneca JPMorgan, AstraZeneca, Amazon, AWS, Meta, General Motors, GMC, Chevrolet, Buick, GM, DFS, Mizuho, Eversource Energy Locations: Avis, MURA, Charlotte, Wayfair, Capital, Macau

☆ I grew up in Italy and have studied longevity for 35 years—this is the No. 1 way to eat for a long, healthy life
▼ + stars: | 2024-04-04 | by ( Renée Onque | ) www.cnbc.com time to read: +1 min

Valter Longo has been studying longevity in Italy for nearly 20 years, but having grown up in regions like Molochio, Calabria, he would say he's been interested in how to live longer basically all of his life. In 1989, Longo officially started researching what it takes to make it to age 100 and beyond. Now, he's the director of the Longevity and Cancer Laboratory at the IFOM Institute of Molecular Oncology in Milan, Italy. Longo is also the director of the Longevity Institute of the Leonard Davis School of Gerontology at the University of Southern California-Los Angeles. Here's what Longo says is the best way to eat for longevity.

Persons: Valter Longo, he's, Longo, Dan Buettner Organizations: Cancer Laboratory, IFOM, Molecular Oncology, Longevity, Leonard Davis School of Gerontology, University of Southern, University of Southern California -, Longo's Locations: Italy, Molochio, Calabria, Milan, University of Southern California, University of Southern California - Los Angeles, Sardinia

The 2024 Sohn Investment Conference took place in New York took place Wednesday, with a slew of hedge fund managers highlighting their top ideas. Here are some of the top picks mentioned: Vijay Shilpiekandula, Dilation Capital Investment Idea: ASML Vijay Shilpiekandula of Dilation Capital, who was named the Sohn Idea Contest Winner, presented ASML as his best stock idea. Jesse Cohn, Elliott Investment Management Investment Idea: Etsy E-commerce platform Etsy is an undervalued company, according to Elliott Investment Management managing partner Jesse Cohn. Seth Fischer, Oasis Management Investment Idea: Kao There's an underappreciated buying opportunity in Japanese global chemicals company Kao, according to Seth Fischer, founder and CIO at Oasis Management. David Einhorn, Greenlight Capital Investment Investment idea: Solvay Greenlight's David Einhorn unveiled Solvay as his top investment idea , saying the European chemicals company is a market leader with an attractive valuation.

Persons: Vijay Shilpiekandula, Vijay, ASML, Shilpiekandula, Jesse Cohn, Etsy, Cohn, Seth Fischer, Kao, Fischer, David Einhorn, Solvay, Einhorn, Michael Buckley, Natera, Buckley, Mohammed Anjarwala, Carpenter, Anjarwala Organizations: Elliott Investment Management Investment, Elliott Investment Management, Body, Oasis Management Investment, Oasis Management, Nikkei, Greenlight Capital Investment Investment, Solvay, Duquesne Family, Duquesne Family Office, Global, Technology Carpenter Technology, Boeing, Airbus Locations: New York, Europe, Bath

☆ Oncologist: Kate’s diagnosis is part of a troubling trend
▼ + stars: | 2024-03-27 | by ( Jalal Baig | ) edition.cnn.com time to read: +7 min

As a medical oncologist, I am heartbroken — but hardly surprised. In fact, it is part of a rising global trend in which newly diagnosed cancer patients are getting younger. The global incidence of early-onset cancer increased by 79.1% and early-onset cancer deaths rose by 27.7% from 1990 to 2019, a 2023 study in the journal BMJ Oncology found. And because early-onset cancers are often diagnosed at advanced stages, they were once thought to be biologically different and more pernicious than their older counterparts. Younger patients may be pregnant at the start of therapy or worry about the effects on fertility.

Persons: Jalal Baig, Catherine , Princess of Wales, Kimmie Ng, “, haven’t, oncologist Jalal Baig, Suneel Kamath, ” Kamath Organizations: Washington Post, NBC News, Foreign, CNN, BMJ Oncology, American Medical Association, Dana, Farber Cancer Institute, Boston Globe, Cleveland Clinic Taussig Cancer Institute, for Young, Cleveland Clinic, US Preventive Services Task Force Locations: Chicago, Washington, United States, Wales

☆ This biotech startup is finding new cancer drugs with $75 million from General Catalyst. Here's the pitch deck Georgiamune used to raise its Series A.
▼ + stars: | 2024-03-26 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +4 min

Then, at the Georgia Cancer Center at Augusta University, he began the research that would eventually spin off into his first startup, Georgiamune. The same month, Georgiamune also got FDA clearance to begin human clinical trials for its first cancer drug candidate. Georgiamune's primary drug target works to solve a problem posed by another type of cancer drug on the market, called checkpoint inhibitors. For a Series A biotech startup, Georgiamune has an unusually extensive pipeline, with nine biological targets identified internally, all of which use different mechanisms of action than existing drugs. AdvertisementHere's the 21-slide pitch deck Georgiamune used to raise a $75 million Series A co-led by General Catalyst.

Persons: —, Samir Khleif, King, Khleif, Catalyst, CJNV BioVenture, Georgiamune, doesn't, Amy Abernethy, Khleif's, General Catalyst Organizations: Service, King Hussein Cancer Center, Georgia Cancer Center, Augusta University, Business, Parker Institute for Cancer, Mubadala, Alexandria Venture Investments, Catalio Capital Management, Verition Fund Management, Bicara Therapeutics, Therapeutics, General Locations: Jordan, Verily

☆ Forget Nvidia: Here are four stocks one investor is betting on instead
▼ + stars: | 2024-03-26 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +6 min

Instead, the veteran wealth manager is now looking for stocks in growth sectors that look "reasonably valued." He said the pharmaceutical, real estate, energy and financial sectors were on his radar, and named four stocks that stand out. Pfizer Pharmaceutical company Pfizer — well known for its Covid-19 vaccine — is betting on cancer drugs , following its $43 billion acquisition of Seagen last year . Over the last 12 months, shares of Comerica are up around 28%, although they are down 7.5% year-to-date. According to Factset data, analysts' average price target on the stock is $59.45, giving it around 15% potential upside.

Persons: David Dietze, Dietze, —, Schlumberger —, Dietze's, SLB Organizations: Nvidia, Wealth Management, Pfizer Pharmaceutical, Pfizer, CNBC Pro, Schlumberger, Comerica Locations: Seagen, U.S, SLB, Canada

☆ AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
▼ + stars: | 2024-03-19 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomesDr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.

Persons: Susan Galbraith Organizations: AstraZeneca, Fusion, Fusion Pharmaceuticals

☆ AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
▼ + stars: | 2024-03-19 | by ( ) www.cnbc.com time to read: +2 min

AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.

Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates

☆ The 'next big thing' in tech will come from these areas, UBS says — naming stocks to play the theme
▼ + stars: | 2024-03-18 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

The "next big thing" in tech will come from sectors such as enabling tech — which includes artificial intelligence and cybersecurity — as well as healthtech, greentech and fintech, UBS said. Here are some names from UBS' list and what it says about each stock. "The medical surgical and neurological business has also returned to strong growth as the pandemic impact fades," the bank said. Broadcom : UBS says that Broadcom boasts a "market-leading" position in semiconductor design. Its greentech picks include French industrial gases and services company Air Liquide , French utility firm Engie , and German chemicals firm Wacker Chemie .

Persons: —, Stryker, ASML, — CNBC's Michael Bloom Organizations: UBS, fintech, Baidu, ASML, Broadcom, 5G, Intercontinental Exchange, Mastercard, Air, Wacker Chemie Locations: Wacker

☆ Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors
▼ + stars: | 2024-03-13 | by ( Brenda Goodman | ) edition.cnn.com time to read: +10 min

Only 3% to 5% of people who are diagnosed with this type of brain tumor will be alive three years later. Now, an experimental therapy that reprograms a person’s own immune cells to attack these tumors is showing some exciting promise. Doctors first harvested immune fighters called T-cells from his blood and then genetically modified them in a lab so they’d recognize and bind to specific proteins on the surface of the brain tumor cells. After a single 10-milliliter infusion of about 10 million CAR-T cells, Fraser’s tumor began to shrink. Three-quarters of the participants had had their brain tumors come back at least twice.

Persons: ”, Otis Brawley, –, they’ll, ” Brawley, Tom Fraser, Brigham, Debbie Fraser, Fraser, He’s, Marcela Maus, ” Fraser, Maus, “, ” Maus, Christine Brown, ’ Brown, ” Brown, hasn’t, Brown, Dr, Donald O’Rourke, “ They’re, O’Rourke, ” O’Rourke, Sanjay Gupta, you’re, they’re, it’s Organizations: CNN, Johns Hopkins University, American Cancer Society, City of Hope Cancer Center, University of Pennsylvania, Massachusetts General, Mass, New England, of Medicine, Doctors, Mass General Cancer Center, Tv3, Cell Therapeutics Research, of, Nature, Penn, Excellence, University of Pennsylvania Perlman School of Medicine, CNN Health Locations: City, Duarte , California, Massachusetts, Rochester , New York, Boston, of Hope, Hope

☆ This risk assessment tool helped Olivia Munn discover her breast cancer
▼ + stars: | 2024-03-13 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +10 min

The “X-Men: Apocalypse” star, 43, wrote in an Instagram post Wednesday that she was diagnosed with breast cancer last year and would not have discovered it if her physician, Dr. Thaïs Aliabadi, had not calculated her breast cancer risk score. A breast cancer risk assessment tool uses a statistical model to estimate a woman’s risk of developing breast cancer over the next five years as well as over her lifetime, or up to about age 90, according to the National Cancer Institute. Two models are commonly used as breast cancer risk assessment tools: the Gail Model and the Tyrer-Cuzick Risk Assessment Calculator. An online version of the breast cancer risk assessment tool, using the Gail Model, is available for anyone to take at bcrisktool.cancer.gov. In fact, some women who do not develop breast cancer have higher risk estimates than some women who do develop breast cancer,” according to the National Cancer Institute’s website.

Persons: Olivia Munn’s, Thaïs Aliabadi, Aliabadi, Munn, Gail, Jennifer Plichta, “, ” Plichta, they’re, ”, Plichta, I’ve, they’ve, Otis Brawley, ” Brawley, Larry Norton, Evelyn H, ” Norton, Robert Smith, Ruth Oratz, NYU Langone Health’s, Dr, Sanjay Gupta, ” Oratz Organizations: CNN, National Cancer Institute, National Cancer, Duke Cancer Institute, Johns Hopkins University, Lauder Breast Center, Memorial Sloan Kettering Cancer Center, American Cancer Society, US Preventive Services Task Force, NYU, Cancer Center, NYU Grossman School of Medicine, CNN Health Locations: United States, Durham , North Carolina

☆ CNBC Daily Open: A mixed picture on U.S. jobs growth
▼ + stars: | 2024-03-11 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. U.S. stocks retreatWall Street finished Friday's session lower as investors look ahead to key inflation data due out this week. Japan skirts technical recessionJapan avoided a technical recession as revised fourth-quarter data revealed the economy returned to growth. "My famous topless sports massage was all about showing our culture, to be honest, that we had such a flexible culture," the Malaysian businessman told CNBC.

Persons: Tony Fernandes, Tasha Keeney Organizations: Grand Central Market, CNBC, Wall, Nasdaq, Dow, Gross, AirAsia, Pfizer Locations: Los Angeles , California, U.S, Japan, Malaysian

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ ‘We’re hemorrhaging money’: US health clinics try to stay open after unprecedented cyberattack
▼ + stars: | 2024-03-09 | by ( Sean Lyngaas | ) edition.cnn.com time to read: +6 min

CNN —For more than two weeks, a cyberattack has disrupted business at health care providers across the United States, forcing small clinics to scramble to stay in business and exposing the fragility of the billing system that underpins American health care. It prevented some insurance payments on prescription drugs from processing, leaving many care providers effectively footing the bill without reimbursement. Health care groups have pleaded with the Department of Health and Human Services (HHS) to offer medical practices a financial lifeline. A week ago, Change Healthcare announced plans for a temporary loan program to get money flowing to health care providers affected by the outage. Tyler Mason, a spokesperson for Change Healthcare, declined to comment when asked if the company had paid off the hackers.

Persons: ”, Catherine Reinheimer, Mel Davies, ” Jesse Ehrenfeld, Reinheimer, Richard Pollack, Carter Groome, ” Groome, Tyler Mason, ALPHV, ” Ari Redbord, Joshua Corman, Corman, “ Organizations: CNN, Change Healthcare, Health, Department of Health, Human Services, Oregon Oncology, Healthcare, American Medical Association, US, Medical Group Management Association, Community Oncology Alliance, American Hospital Association, Justice Department, ALPHV, Labs Locations: United States, Philadelphia, UnitedHealth, Oregon

☆ Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40%
▼ + stars: | 2024-03-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Newly public biotech Kyverna Therapeutics could be a blockbuster cell therapy developer for autoimmune disease, according to Morgan Stanley. The stock opened at $34.25, above the initial public offering price of $22 per share, and closed Friday at $27.75. Although the data from KYV-101 is limited, Ulz wrote that he's "highly encouraged given promising results across multiple indications, multiple sites, and in challenging patients." The analyst pointed out that cell therapies have "meaningfully improved" the treatment of B-cell cancers and that multiple therapies are currently approved, increasing the therapies' potential to treat autoimmune diseases. Ingenui-T is a next-generation process in preclinical development for manufacturing autologous anti-CD19 CAR T-cell therapy, and uses the same CAR construct as KYV-101, Kyverna said.

Persons: Morgan Stanley, Michael Ulz, Kyverna, Ulz Organizations: Therapeutics, Nasdaq, autoimmunity Locations: KYV, Kyverna

Search resuls for: "Oncology"

25 mentions found